EUVIMEDEUVIMED entdecken
Open Access

Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real‐World Short‐Term Data on Tolerability, Infusion Rate Adjustments and Concomitant Medication

Katarina Rukavina iD, Georg Ebersbach, Doreen Gruber

Movement Disorders Clinical Practice · 2025-12 · 12 (12) · 2317-2323

DOI: 10.1002/mdc3.70249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 28.07.2025. Verfasst von Katarina Rukavina und 2 weiteren Autor:innen. Beteiligte Einrichtung: Movement Disorders Hospital Beelitz, Beelitz-Heilstätten, Germany. Hauptthemen laut MEDLINE: Parkinson Disease, Antiparkinson Agents, Levodopa, Carbidopa. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Foslevodopa/foscarbidopa (LDp/CDp) significantly reduced motor fluctuations in people with Parkinson's disease (PwP) in clinical trials, but its real‐world tolerability and optimal dosing remain unclear.

Objectives

To assess tolerability, dosing patterns, and modifications to concomitant medication with LDp/CDp in clinical practice.

Methods

A single‐center retrospective cross‐sectional analysis.

Results

The LDp/CDp was initiated in 53 PwP (41% women, mean age 66 ± 11.3 years, mean disease duration 14.1 ± 5.7 years, median H&Y 4 (3–5); history of cognitive impairment: 40%, history of psychosis: 62%, previous device aided therapies failure: 39%). After an optimization period (18.4 ± 6.8 days), the mean Base hourly infusion rate was significantly higher than recommended (0.39 ± 0.18 vs. 0.32 ± 0.13 ml/h, p < 0.001) and the LDp/CDp was co‐administered with MAO‐B‐inhibitors (50%), COMT‐inhibitors (44%), and dopamine agonists (12%). Adverse events occurred in 40%: skin reactions (31%), psychosis (8%), falls (2%), and nausea (2%). Thirteen patients discontinued therapy.

Conclusions

LDp/CDp may be an effective and well‐tolerated non‐surgical option for managing motor fluctuations in PD, though higher dosing and combination therapy are often required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseAntiparkinson AgentsLevodopaCarbidopaHumansFemaleAgedMaleCross-Sectional StudiesRetrospective StudiesMiddle AgedDrug CombinationsInfusions, Subcutaneous

Stichwörter der Autor:innen

advanced Parkinson's diseasedevice aided therapiesinfusion therapiesmotor complicationsmotor fluctuations

Substanzen

Drug CombinationsAntiparkinson AgentsLevodopaCarbidopacarbidopa, levodopa drug combination

Autor:innen und Institutionen

  • Movement Disorders Hospital Beelitz, Beelitz-Heilstätten, Germany.
  • Medical faculty, Health and Medical University Potsdam, Potsdam, Germany.
  • Department of Neurology, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.

ORCID-Profile: Katarina Rukavina

Zitieren

APA

Rukavina, K., Ebersbach, G., & Gruber, D. (2025). Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real‐World Short‐Term Data on Tolerability, Infusion Rate Adjustments and Concomitant Medication. Movement Disorders Clinical Practice, 12(12), 2317-2323. https://doi.org/10.1002/mdc3.70249

Vancouver

Rukavina K, Ebersbach G, Gruber D. Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real‐World Short‐Term Data on Tolerability, Infusion Rate Adjustments and Concomitant Medication. Movement Disorders Clinical Practice. 2025;12(12):2317-2323. doi:10.1002/mdc3.70249

BibTeX
@article{Rukavina2025,
  author = {Rukavina, Katarina and Ebersbach, Georg and Gruber, Doreen},
  title = {Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease: Real‐World Short‐Term Data on Tolerability, Infusion Rate Adjustments and Concomitant Medication},
  journal = {Movement Disorders Clinical Practice},
  year = {2025},
  volume = {12},
  number = {12},
  pages = {2317--2323},
  doi = {10.1002/mdc3.70249}
}
Kostenlos starten →